Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amin Rostami

Showing results (1-10 of 305) with videos related to

Pageof 31
Sort By:
Biopharmaceutics & Drug Disposition|March 14, 2015
Complex patients - complex DDI: is there a straight way forward?Amin Rostami-Hodjegan
Drug Metabolism and Pharmacokinetics|January 6, 2026
Positive implications of PBPK platform qualification for predicting drug-drug interactions: Taking on cracks only to see bigger gaps!Amin Rostami-Hodjegan
Clinical Pharmacology and Therapeutics|October 13, 2017
Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With ConfidenceAmin Rostami-Hodjegan
Clinical Pharmacology and Therapeutics|December 22, 2017
Revisiting Principles Behind Drug Clearance and Organ ExtractionAmin Rostami-Hodjegan
Scientific Reports|July 2, 2025
The single Fe atoms and DDQ catalyst system for the aerobic dehydrogenation of dihydropyridines and dihydroquinazolinonesHamzeh Veisi, Amin Rostami
RSC Advances|October 2, 2025
Application of layered double hydroxides as laccase mimicking nanozymes in the oxidation of 2,3-dihydroquinazolin-4(1<i>H</i>)-ones and hantzsch 1,4-dihydropyridinesNadia Ghorashi, Amin Rostami
Clinical Pharmacology and Therapeutics|September 21, 2022
Is Liquid Biopsy Only Restricted to Diagnostics or Can it Go Beyond the Confines of Genotyping and Phenotyping for Quantitative Pharmacology?Brahim Achour, Amin Rostami-Hodjegan
Pharmaceutical Research|April 21, 2022
Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?Sebastian Frechen, Amin Rostami-Hodjegan
Drug Discovery Today. Technologies|July 2, 2014
'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactionsAmin Rostami-Hodjegan, Geoff Tucker
Biopharmaceutics & Drug Disposition|August 25, 2023
Linking in vitro-in vivo extrapolations with physiologically based modeling to inform drug and formulation developmentRodrigo Cristofoletti, Amin Rostami-Hodjegan
Pageof 31

Showing results (1-10 of 305) with videos related to

Sort By:
Pageof 31
Biopharmaceutics & Drug Disposition|March 14, 2015
Complex patients - complex DDI: is there a straight way forward?Amin Rostami-Hodjegan
Drug Metabolism and Pharmacokinetics|January 6, 2026
Positive implications of PBPK platform qualification for predicting drug-drug interactions: Taking on cracks only to see bigger gaps!Amin Rostami-Hodjegan
Clinical Pharmacology and Therapeutics|October 13, 2017
Reverse Translation in PBPK and QSP: Going Backwards in Order to Go Forward With ConfidenceAmin Rostami-Hodjegan
Clinical Pharmacology and Therapeutics|December 22, 2017
Revisiting Principles Behind Drug Clearance and Organ ExtractionAmin Rostami-Hodjegan
Scientific Reports|July 2, 2025
The single Fe atoms and DDQ catalyst system for the aerobic dehydrogenation of dihydropyridines and dihydroquinazolinonesHamzeh Veisi, Amin Rostami
RSC Advances|October 2, 2025
Application of layered double hydroxides as laccase mimicking nanozymes in the oxidation of 2,3-dihydroquinazolin-4(1<i>H</i>)-ones and hantzsch 1,4-dihydropyridinesNadia Ghorashi, Amin Rostami
Clinical Pharmacology and Therapeutics|September 21, 2022
Is Liquid Biopsy Only Restricted to Diagnostics or Can it Go Beyond the Confines of Genotyping and Phenotyping for Quantitative Pharmacology?Brahim Achour, Amin Rostami-Hodjegan
Pharmaceutical Research|April 21, 2022
Quality Assurance of PBPK Modeling Platforms and Guidance on Building, Evaluating, Verifying and Applying PBPK Models Prudently under the Umbrella of Qualification: Why, When, What, How and By Whom?Sebastian Frechen, Amin Rostami-Hodjegan
Drug Discovery Today. Technologies|July 2, 2014
'In silico' simulations to assess the 'in vivo' consequences of 'in vitro' metabolic drug-drug interactionsAmin Rostami-Hodjegan, Geoff Tucker
Biopharmaceutics & Drug Disposition|August 25, 2023
Linking in vitro-in vivo extrapolations with physiologically based modeling to inform drug and formulation developmentRodrigo Cristofoletti, Amin Rostami-Hodjegan
Pageof 31